Tempest Therapeutics (TPST) risk factors
Item 1A of every Tempest Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors90 risks23 new10 dropped25 reworded
Tempest added a dual-targeting CAR-T pipeline and clinical trial collaborations via an asset acquisition, while battling going concern doubts and a skeletal headcount.
Filed Mar 30, 2026 - FY2024 10-K risk factors77 risks
Tempest Therapeutics faces primary risks from its heavy reliance on two unapproved lead product candidates, amezalpat and TPST-1495. The company requires significant ongoing capital and debt financing, pledging all assets including intellectual property to Oxford Finance. Clinical development, trial patient enrollment, and third-party manufacturing dependencies present continuous operational threats.
Filed Mar 27, 2025